Research Calls
-
Upgrades:
- America Movil SA (AMX) upgraded to Buy from Neutral at Goldman; tgt raised to $22
- Apple (AAPL) upgraded to Outperform from Mkt Perform at Bernstein; tgt $195
- Axsome Therapeutics (AXSM) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $115
- Eastman Chemical (EMN) upgraded to Buy from Hold at Jefferies; tgt raised to $125
- FirstCash (FCFS) upgraded to Buy from Hold at Loop Capital; tgt raised to $140
- General Dynamics (GD) upgraded to Buy from Hold at Jefferies; tgt raised to $335
- Grainger (GWW) upgraded to Overweight from Equal-Weight at Stephens; tgt raised to $1250
-
Downgrades:
- Acrivon Therapeutics (ACRV) downgraded to Neutral from Buy at Ladenburg Thalmann
- Altimmune (ALT) downgraded to Neutral from Buy at Guggenheim
- Enerplus (ERF) downgraded to Sector Perform from Outperform at RBC Capital Mkts; tgt raised to $22
-
Others:
- AAON (AAON) initiated with an Outperform at William Blair
- Abivax SA (ABVX) initiated with a Buy at Guggenheim; tgt $50
- Abivax SA (ABVX) initiated with an Overweight at Piper Sandler; tgt $42
- Dave, Inc. (DAVE) initiated with a Mkt Outperform at JMP Securities; tgt $70
- Geron (GERN) initiated with a Buy at TD Cowen; tgt $10
- Immunocore (IMCR) initiated with an Outperform at Leerink Partners; tgt $74